159 related articles for article (PubMed ID: 34328202)
1. Urantide prevents CCl4‑induced acute liver injury in rats by regulating the MAPK signalling pathway.
Li Y; Guo Z; Cui H; Wang T; Xu Y; Zhao J
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328202
[TBL] [Abstract][Full Text] [Related]
2. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway.
Zhao J; Miao G; Wang T; Li J; Xie L
Life Sci; 2020 Dec; 262():118551. PubMed ID: 33038370
[TBL] [Abstract][Full Text] [Related]
3. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats.
Wang T; Xie YQ; Miao GX; Cui HP; Liu K; Li Y; Li Y; Zhao J
Life Sci; 2020 Apr; 247():117421. PubMed ID: 32061865
[TBL] [Abstract][Full Text] [Related]
4. Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway.
Cui H; Lin Y; Xie L; Zhao J
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33604686
[TBL] [Abstract][Full Text] [Related]
5. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Wang T; Xie L; Bi H; Li Y; Li Y; Zhao J
Eur J Pharmacol; 2021 Jul; 902():174037. PubMed ID: 33891969
[TBL] [Abstract][Full Text] [Related]
6. The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway.
Wang T; Sun X; Cui H; Liu K; Zhao J
Mol Med Rep; 2020 Mar; 21(3):1097-1106. PubMed ID: 32016456
[TBL] [Abstract][Full Text] [Related]
7. The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells.
Liu LM; Liang DY; Ye CG; Tu WJ; Zhu T
PLoS One; 2015; 10(3):e0121383. PubMed ID: 25803040
[TBL] [Abstract][Full Text] [Related]
8. Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations.
Dong X; Ye X; Song N; Zhao J; Di B; Peng F; Tang C; Ding W
Heart Vessels; 2013 Jul; 28(4):514-23. PubMed ID: 23053343
[TBL] [Abstract][Full Text] [Related]
9. IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.
Liu LM; Tu WJ; Zhu T; Wang XT; Tan ZL; Zhong H; Gao DY; Liang DY
Oncotarget; 2016 Aug; 7(31):49027-49041. PubMed ID: 27448985
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.
Liang DY; Liu LM; Ye CG; Zhao L; Yu FP; Gao DY; Wang YY; Yang ZW; Wang YY
PLoS One; 2014; 8(6):e64895. PubMed ID: 23755157
[TBL] [Abstract][Full Text] [Related]
11. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats.
Matsumoto T; Watanabe S; Kobayashi S; Ando M; Taguchi K; Kobayashi T
Rejuvenation Res; 2017 Apr; 20(2):134-145. PubMed ID: 27841739
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of urotensin II and its receptor in diethylnitrosamine-mediated precancerous lesions in rat liver.
Wang H; Dong K; Xue X; Feng P; Wang X
Peptides; 2011 Feb; 32(2):382-7. PubMed ID: 21056072
[TBL] [Abstract][Full Text] [Related]
13. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
[TBL] [Abstract][Full Text] [Related]
14. Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(-/-) mice.
Xu YH; Xie JY; Huang S; Wang T; Cui HP; Zhao J
Herz; 2023 Nov; ():. PubMed ID: 37985514
[TBL] [Abstract][Full Text] [Related]
15. Urotensin II contributes to collagen synthesis and up-regulates Egr-1 expression in cultured pulmonary arterial smooth muscle cells through the ERK1/2 pathway.
Li W; Cai Z; Liu M; Zhao C; Li D; Lv C; Wang Y; Xu T
Biochem Biophys Res Commun; 2015 Nov; 467(4):1076-82. PubMed ID: 26431877
[TBL] [Abstract][Full Text] [Related]
16. Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.
Gao S; Oh YB; Shah A; Park WH; Chung MJ; Lee YH; Kim SH
Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H1782-9. PubMed ID: 20870804
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways.
Yu XT; Wang PY; Shi ZM; Dong K; Feng P; Wang HX; Wang XJ
Molecules; 2014 Dec; 19(12):20768-79. PubMed ID: 25514221
[TBL] [Abstract][Full Text] [Related]
18. Urotensin-II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin-induced acute kidney injury.
Nitescu N; Grimberg E; Guron G
Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1170-5. PubMed ID: 20880186
[TBL] [Abstract][Full Text] [Related]
19. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
20. Urotensin II inhibits skeletal muscle glucose transport signaling pathways via the NADPH oxidase pathway.
Wang HX; Wu XR; Yang H; Yin CL; Shi LJ; Wang XJ
PLoS One; 2013; 8(10):e76796. PubMed ID: 24116164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
